Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedJan 25, 2026
DataAggregated Company Financials
Companies5
  • 7D-1.7%
  • 3M4.3%
  • 1Y8.2%
  • YTD3.3%

Over the last 7 days, the Biotech industry has dropped 1.7%, driven by a pullback from Genmab of 2.5%. This takes the industry's 12 month performance to a gain of 8.2%. In the next few years, earnings are forecast to decline by 5.3% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 25 Jan 2026DKK 177.3bDKK 40.4bDKK 18.9b6.3x9.4x4.4x
Tue, 23 Dec 2025DKK 176.8bDKK 40.5bDKK 19.0b6.1x9.3x4.4x
Thu, 20 Nov 2025DKK 172.6bDKK 41.0bDKK 19.1b5.9x9x4.2x
Sat, 18 Oct 2025DKK 180.0bDKK 38.9bDKK 16.8b13.1x10.7x4.6x
Mon, 15 Sep 2025DKK 158.8bDKK 38.8bDKK 16.7b12.7x9.5x4.1x
Wed, 13 Aug 2025DKK 128.6bDKK 29.6bDKK 8.8b11.9x14.6x4.3x
Fri, 11 Jul 2025DKK 127.6bDKK 26.9bDKK 7.3b11.3x17.4x4.7x
Sun, 08 Jun 2025DKK 137.5bDKK 27.5bDKK 7.5b11.3x18.3x5x
Tue, 06 May 2025DKK 136.3bDKK 27.3bDKK 7.7b11.9x17.7x5x
Thu, 03 Apr 2025DKK 126.3bDKK 27.3bDKK 7.7b11.1x16.4x4.6x
Sat, 01 Mar 2025DKK 165.7bDKK 27.7bDKK 7.8b12.4x21.2x6x
Mon, 27 Jan 2025DKK 166.7bDKK 26.0bDKK 4.7b17.1x35.5x6.4x
Wed, 25 Dec 2024DKK 160.6bDKK 26.0bDKK 4.7b16.6x34.2x6.2x
Fri, 22 Nov 2024DKK 157.0bDKK 26.0bDKK 4.7b16.5x33.4x6x
Sun, 20 Oct 2024DKK 174.2bDKK 25.5bDKK 5.5b21x31.8x6.8x
Tue, 17 Sep 2024DKK 198.1bDKK 25.5bDKK 5.5b24x36.2x7.8x
Thu, 15 Aug 2024DKK 198.2bDKK 26.0bDKK 5.7b19.2x34.7x7.6x
Sat, 13 Jul 2024DKK 197.3bDKK 24.8bDKK 5.6b17.7x35x8x
Mon, 10 Jun 2024DKK 179.2bDKK 24.8bDKK 5.6b18.5x31.8x7.2x
Wed, 08 May 2024DKK 184.3bDKK 25.2bDKK 6.2b16.2x29.9x7.3x
Fri, 05 Apr 2024DKK 188.4bDKK 23.9bDKK 5.0b19.7x37.4x7.9x
Sun, 03 Mar 2024DKK 184.8bDKK 22.8bDKK 4.3b23.5x43.2x8.1x
Tue, 30 Jan 2024DKK 168.1bDKK 23.3bDKK 4.2b23x40.4x7.2x
Thu, 28 Dec 2023DKK 176.2bDKK 23.3bDKK 4.2b25.9x42.3x7.6x
Sat, 25 Nov 2023DKK 172.7bDKK 23.3bDKK 4.2b25x41.5x7.4x
Mon, 23 Oct 2023DKK 162.9bDKK 22.0bDKK 4.7b18.9x34.4x7.4x
Wed, 20 Sep 2023DKK 199.5bDKK 22.0bDKK 4.7b23.4x42.1x9.1x
Fri, 18 Aug 2023DKK 188.2bDKK 20.6bDKK 3.9b35.9x48.6x9.1x
Sun, 16 Jul 2023DKK 200.5bDKK 19.5bDKK 4.4b40.9x45.5x10.3x
Tue, 13 Jun 2023DKK 209.4bDKK 19.5bDKK 4.4b44.7x47.5x10.7x
Thu, 11 May 2023DKK 207.4bDKK 18.6bDKK 3.9b33.7x53.8x11.1x
Sat, 08 Apr 2023DKK 199.2bDKK 17.9bDKK 3.5b31x56.3x11.1x
Mon, 06 Mar 2023DKK 197.5bDKK 17.9bDKK 3.5b30.4x55.7x11x
Wed, 01 Feb 2023DKK 201.9bDKK 14.7bDKK 3.3b30.9x61.7x13.7x
Price to Earnings Ratio

61.7x


Total Market Cap: DKK 201.9bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 32.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.4x which is lower than its 3-year average PE of 32.6x.
  • The 3-year average PS ratio of 7.3x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 79% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market0.0065%
Healthcare1.77%
Biotech-1.66%
Biotech-1.66%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZEAL Zealand PharmaDKK 426.001.5%
+DKK 457.8m		-45.3%PE4.6x

Latest News

BAVA
DKK 198.65
Bavarian Nordic
7D
-0.3%
1Y
-0.3%

BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings

Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.
GMAB
DKK 2,130.00
Genmab
7D
-2.5%
1Y
41.7%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
ZEAL
DKK 426.00
Zealand Pharma
7D
1.5%
1Y
-45.3%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
BIOPOR
DKK 1.01
BioPorto
7D
-4.7%
1Y
-33.4%
STRAP
DKK 704.00
Strategic Partners
7D
-1.7%
1Y
-20.5%